Achieve Life Sciences (ACHV) Stock Price, Quote, News & History | Benzinga

SPY762.36−1.22%QQQ709.32−2.57%BTC/USD81,660.61−0.57%DIA519.08−0.38%GLD381.71−0.26%TLT80.05+0.10%

Achieve Life Sciences Inc (ACHV) Stock Price, Quote, News & History

ACHVNASDAQ

Trade with Public

Trade with Public

$6.38

-0.59-8.46%

Last update: Oct 16, 4:27 PM

$6.38

-0.59-8.46%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$6.98

Close

$6.38

Volume / Avg.

1.99M / 1.41M

Day Range

$6.38 - $6.38

52 Wk Range

2.62 - 8.64

Market Cap

$721.72M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

34

Short Interest

17.04%

Days to Cover

10.88

Recent Achieve Life Sciences, Inc. News

This Vail Resorts Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Wall Street analysts changed outlook on top names. Check analyst ratings page for all changes. See what analysts think of MTN stock.

Avi Kapoor

Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures mostly higher, Nasdaq up by 100 points. Phoenix Education falls after cutting sales guidance. Other stocks also down in pre-market.

Avi Kapoor

FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned

FDA rejects Achieve Life Sciences application for cytisinicline tied to manufacturing issues, with NDA resubmission planned in Q4 2026.

Vandana Singh

SPCX, INTC, NFLX And More: 5 Stocks Investors Couldn't Stop Buzzing About This Week

Retail investors talked up five hot stocks this week (June 15 to June 18) on X and Reddit's r/WallStreetBets: SPCX, MSFT, NFLX, INTC, ACHV.

Rishabh Mishra

Achieve Life Sciences Flags FDA Observations While Pushing Launch To 2027 For Smoking Cessation Med

Achieve Life Sciences taps Adare for cytisinicline manufacturing as stock falls; reports wider losses and shifts US launch timeline to 2027.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-47.02M

Investing Cash Flow (TTM)

-135.47M

Financing Cash Flow (TTM)

178.78M

Free Cash Flow (TTM)

-47.21M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-3.71M

Analyst Trends and Forecast

1

Apr

1

Jun

1

Aug

1

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$546.78M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-23.80%

Earnings Yield % (FWD)

-11.04%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.14

Company Debt

Total Debt

$14.91M

LT Debt

$7.46M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$47.96M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-